Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTI-1090
- Development stage
- Phase 1
- Lead developer
- Atridia
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HTI-1090 (also known as SHR9146) is an orally available small molecule that acts as a dual inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO). By inhibiting these enzymes involved in the kynurenine pathway of tryptophan metabolism, HTI-1090 has potential immunomodulatory and antineoplastic effects. The drug is being developed primarily for the treatment of advanced solid tumors. IDO1 and TDO are implicated in tumor immune evasion by depleting tryptophan and producing immunosuppressive metabolites; their inhibition may restore anti-tumor immune responses. The drug was originally developed by Jiangsu Hengrui Medicine Co., with development also involving Atridia/Hengrui Therapeutics[1][2][4][5].
- Other names
- HTI-1090HTI1090HTI 1090SHR9146SHR-9146SHR 9146
02
Targets
TDO2 (Tryptophan 2,3-dioxygenase)IDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on HTI-1090.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTI-1090.